source
- Hengrui secures $15.2 billion Bristol Myers deal and pivots to co-development with Western partnersHengrui Pharmaceuticals has become a leading source of innovative drugs in China, outpacing many peers in the current licensing boom. In May the company signed a $15.2 billion licensing pact with…
- FDA flags safety concern after four deaths in schizophrenia drug trialThe U.S. Food and Drug Administration issued a warning after four participants died while receiving an experimental treatment for schizophrenia in a clinical study. The agency described the observ…